Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab vs Standard Therapy in dMMR/MSI-H Stage III Colorectal Cancer
NCT05236972Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in colon cancer, sponsored by Sun Yat-sen University. Started Jan 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05236972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236972.